AE Wealth Management LLC trimmed its position in MeiraGTx Holdings PLC (NASDAQ:MGTX) by 7.0% in the third quarter, HoldingsChannel.com reports. The firm owned 123,921 shares of the company’s stock after selling 9,336 shares during the quarter. AE Wealth Management LLC’s holdings in MeiraGTx were worth $1,977,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Bank of Montreal Can acquired a new stake in MeiraGTx during the 2nd quarter valued at $35,000. Meeder Asset Management Inc. boosted its holdings in MeiraGTx by 2,168.0% in the third quarter. Meeder Asset Management Inc. now owns 3,334 shares of the company’s stock worth $53,000 after purchasing an additional 3,187 shares in the last quarter. Focused Wealth Management Inc bought a new stake in MeiraGTx in the second quarter worth $57,000. Tower Research Capital LLC TRC bought a new stake in MeiraGTx in the third quarter worth $72,000. Finally, Bowling Portfolio Management LLC bought a new stake in MeiraGTx in the third quarter worth $216,000. Hedge funds and other institutional investors own 37.54% of the company’s stock.
Shares of NASDAQ:MGTX opened at $14.72 on Friday. The stock has a market capitalization of $515.22 million, a PE ratio of -3.35 and a beta of 2.05. MeiraGTx Holdings PLC has a 1 year low of $8.53 and a 1 year high of $30.23. The firm has a fifty day moving average price of $15.03 and a 200 day moving average price of $20.81. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.12.
MGTX has been the subject of a number of recent research reports. Piper Jaffray Companies initiated coverage on shares of MeiraGTx in a report on Tuesday, September 3rd. They issued an “overweight” rating and a $40.00 price objective for the company. Zacks Investment Research upgraded shares of MeiraGTx from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a report on Wednesday. Chardan Capital reiterated a “buy” rating and issued a $45.00 price objective on shares of MeiraGTx in a report on Monday, September 23rd. Finally, ValuEngine upgraded shares of MeiraGTx from a “sell” rating to a “hold” rating in a report on Thursday, October 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $33.00.
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.
Want to see what other hedge funds are holding MGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MeiraGTx Holdings PLC (NASDAQ:MGTX).
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.